We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Method Corrects Automated Hemoglobin Measurement Interference

By LabMedica International staff writers
Posted on 30 Oct 2013
Hypertriglyceridemia is a well-known factor that can interfere with the measurement of hemoglobin (HGB) using automated hematology analyzers and it can cause falsely high HGB values.

A simple but effective correction method has been introduced to rectify the interference of high blood triglyceride (TG) levels in measurement of blood HGB by automated hematology analyzers commonly used in clinical laboratories.

Clinical laboratorians at the Sichuan University (Chengdu, China) analyzed 50 whole blood samples and 50 plasma samples containing variable TG concentrations. More...
Complete blood cell counts (CBCs) were performed by an XE-2100 automated hematology analyzer (Sysmex; Kobe, Japan) for 102 blood samples, in which high-level TG were artificially added. The same blood samples were centrifuged at different speeds to separate the plasma from blood cells. An optimal centrifugal force and time were identified to separate plasma and blood cells and to exert the least influence on the chylomicrons (CMs) in the plasma, which was then analyzed.

By using the two CBC results, a correction formula was established to calculate the corrected HGB, mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) values. Comparisons were also made of HGB, MCH, and MCHC values before and after correction of in-patient individuals who received intralipid and developed lipemia. The percentage differences between the corrected and true values of HGB, MCH and MCHC were −0.28%, 0.06%, and −0.31%, respectively. The correlation coefficients of corrected values versus true values of HGB, MCH, and MCHC were 0.989, 0.935, and 0.717, respectively. This correction method was also effective for native lipemic samples.

The authors concluded that by adding a simple step of low-speed centrifugation, their method was able to provide reliable results of HGB, MCH, and MCHC in highly lipemic blood samples without special equipment. This provided evidence that the HGB concentration of intralipid and plasma mixture was not affected by different centrifugal conditions. Therefore, they recommended that the least time-consuming centrifugation parameter be adopted. The study was published on September 13, 2013, in the Journal of Clinical Laboratory Analysis.

Related Links:

Sichuan University
Sysmex



New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.